Clinical trial · Observational
Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients
Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients; a Cross-Sectional Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this large-scale cross-sectional study, we evaluated disease-free survival (DFS), overall survival (OS), and clinicopathological characteristics of BC patients from 1991 to 2022, retrospectively. We recruited patients referred to the Cancer Research Center in Tehran, Iran, and their HER2 status, which is classified as HER2-low, HER2-positive, or HER2-negative, was obtained from prospectively maintained registries. we aimed to dive more deeply into the clinicopathological characteristics and survival features of HER2-low breast cancer patients and campared it with HER2-negative and HER2-positive groups. Question 1: Is HER2-low breast cancer (BC) a new subtype in the standard classification of BCs? Question 2: How is the DFS and OS rate of HER2-low breast cancer patients in comparison with HER2-negative and HER2-positive groups?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2 Low Breast Carcinoma | HER2-Low Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunohistochemistry (IHC) and in situ hybridization (ISH) Test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- HER2-low
- description
- patients with HER2 IHC1+ and HER2 IHC2+/ISH-negative in their pathology
- interventionNames
- Diagnostic Test: immunohistochemistry (IHC) and in situ hybridization (ISH) Test
- label
- HER2-negative
- description
- patients with HER2-zero in their pathology
- interventionNames
- Diagnostic Test: immunohistochemistry (IHC) and in situ hybridization (ISH) Test
- label
- HER2-positive
- description
- patients with HER2 IHC2+/ISH-positive and HER2 IHC 3+ in their pathology
- interventionNames
- Diagnostic Test: immunohistochemistry (IHC) and in situ hybridization (ISH) Test
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: All breast cancer patients with human epidermal growth factor receptor 2 (HER2) status in the database of the Cancer Research Center (CRC),from April 1991 to March 2022 Exclusion Criteria: The male gender Patients with indeterminate or missing HER2 status, or patients with missing DFS and OS information
References
Publications (1)
- DERIVEDAbbasvandi F, Bayat M, Akbari A, Shojaeian F, Zandi A, Rahmani J, Hashemi MO, Akbari ME. Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study. Sci Rep. 2023 Oct 4;13(1):16719. doi: 10.1038/s41598-023-43186-8. PMID 37794050